Skip to content

A clinical study for Tan-Re-Qing injection in the treatment of community-acquired pneumonia patients with fever

A clinical study for Tan-Re-Qing injection in the treatment of community-acquired pneumonia patients with fever

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022635
Enrollment
Unknown
Registered
2019-04-19
Start date
2019-04-16
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fever patients with community-acquired pneumonia

Interventions

Experimental group:Tanreqing + single antibiotic
Control group:single antibiotic

Sponsors

The 967th Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic standards of western medicine and traditional Chinese medicine for community-acquired pneumonia; (2) Into the group when the body temperature of 37.4 degree C or more patients with fever in the hospital; (3) Comply with the ethical requirements, aged between 18 and 75 years old, male or female; (4) Informed consent and volunteer.

Exclusion criteria

Exclusion criteria: (1) The patient is a minor with the age <18 years old or a woman during pregnancy or lactation; (2) Randomly enrolled patients who had been treated with antipyretic drugs, such as aspirin, acetaminophen and other non-steroidal anti-inflammatory drugs, and chlorpromazine within 6 hours before medication; (3) Participated in other clinical researchers 3 months before the trial; (4) Patients with severe diseases of the heart, brain, kidney, hematopoietic system, and unstable disease control when seeking medical treatment; (5) Allergic to the known components of tanreqing injection; (6) The patient is taking adrenal steroids (except for external use) or immunosuppressive agents; (7) Mental patients, alcoholics or those with a history of drug abuse; (8) With intravenous infusion disorder; (9) The researchers believe that other reasons are not suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
The time of fever relieving;

Secondary

MeasureTime frame
Rate of disappearance on the third day of fever;The length of time;Leukocyte count;Percentage of neutrophils;

Countries

China

Contacts

Public ContactLiu Zhongyang

The 967th Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army

2030622263@qq.com+86 15524642685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026